Literature DB >> 12801256

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment.

B Sorbe1.   

Abstract

In a prospective randomized trial, consolidation treatment with radiotherapy or chemotherapy was compared with no treatment in a series of 172 patients with epithelial ovarian carcinoma, FIGO stage III, with complete surgical remission after primary cytoreductive surgery and induction chemotherapy. In the subgroup with complete surgical and pathologic remission, progression-free survival was significantly (P = 0.032) better in the radiotherapy group (56% at 5 years) than in the chemotherapy group (36% at 5 years) and the untreated control group (35% at 5 years). Overall survival was also most favorable in the radiotherapy group (69% at 5 years). The number of recurrences was lowest in the radiotherapy group. In the subgroup with microscopic residual carcinoma there were no significant differences in survival between the radiotherapy and the chemotherapy-treated patients. Early and late radiation reactions were recorded. Treatment-related side effects were seen most frequently in the radiotherapy group. Late intestinal radiation reactions of a severe type were recorded in 10%.

Entities:  

Mesh:

Year:  2003        PMID: 12801256     DOI: 10.1046/j.1525-1438.2003.13193.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  23 in total

1.  Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.

Authors:  Lisa M Hess; Nan Rong; Patrick O Monahan; Paridha Gupta; Champ Thomaskutty; Daniela Matei
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

2.  Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional Experience.

Authors:  Anshuma Bansal; Bhavana Rai; Shikhar Kumar; Vanita Suri; Sushmita Ghoshal
Journal:  J Obstet Gynaecol India       Date:  2016-07-29

3.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

4.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

5.  Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.

Authors:  Nathalie Rochet; Katja Lindel; Sonja Katayama; Kai Schubert; Klaus Herfarth; Andreas Schneeweiss; Christoph Sohn; Wolfgang Harms; Juergen Debus
Journal:  Strahlenther Onkol       Date:  2015-03-19       Impact factor: 3.621

6.  Whole abdomen radiation therapy in ovarian cancers: a comparison between fixed beam and volumetric arc based intensity modulation.

Authors:  Umesh Mahantshetty; Swamidas Jamema; Reena Engineer; Deepak Deshpande; Rajiv Sarin; Antonella Fogliata; Giorgia Nicolini; Alessandro Clivio; Eugenio Vanetti; Shyamkishore Shrivastava; Luca Cozzi
Journal:  Radiat Oncol       Date:  2010-11-15       Impact factor: 3.481

7.  Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy.

Authors:  Jee Suk Chang; Woong Sub Koom; Sang Wun Kim; Sunghoon Kim; Yong Bae Kim; Young Tae Kim; Gwi Eon Kim
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

8.  Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.

Authors:  Nathalie Rochet; Meinhard Kieser; Florian Sterzing; Sonja Krause; Katja Lindel; Wolfgang Harms; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus
Journal:  BMC Cancer       Date:  2011-01-28       Impact factor: 4.430

Review 9.  Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.

Authors:  Aramide O Lawal; Alfred Musekiwa; Liesl Grobler
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

Review 10.  Maintenance chemotherapy for ovarian cancer.

Authors:  Ling Mei; Hui Chen; Dong Mei Wei; Fang Fang; Guan J Liu; Huan Yu Xie; Xun Wang; Juan Zou; Xu Han; Dan Feng
Journal:  Cochrane Database Syst Rev       Date:  2013-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.